Effects of LIraglutide on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging
Effects of LIraglutide on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging
Type II diabetes is a known risk factor for heart failure, particularly through the
 progressive development of diabetic cardiomyopathy. Cardiac metabolic parameters, including
 myocardial steatosis and epicardial fat, are altered in diabetic patients. The development of
 new anti-diabetics (incretins) has demonstrated protective cardiovascular effects independent
 of effects on glycemic control for the first time in the history of these therapies. Thus
 Glucagon-Like Peptide 1 (GLP-1) agonists improve the recovery of cardiac function after a
 heart attack and decrease atheromatous processes. It has also been demonstrated in a diabetic
 rat model that the administration of Liraglutide, a GLP-1 agonist, leads to normalization of
 myocardial steatosis associated with beneficial cardiac molecular remodeling involving
 pro-apoptotic, oxidative and metabolic processes. These beneficial cardiovascular effects
 were observed in the absence of any changes in blood glucose, insulin levels or body weight.
Inclusion Criteria:

 -  Patient who has given consent

 -  Adult patient over the age of 50 for men and over 60 for women

 -  Type II diabetes treated without modification of antidiabetic treatment in the
 previous 3 months

 -  HbA1c ≥ 7.5%

 -  At least one of:

 -  treated high blood pressure,

 -  obesity (BMI>30 kg/m2),

 -  treated dyslipidemia,

 -  Active smoking (from 1 cigarette per day) or quit less than 3 years ago,

 -  hereditary coronary heart disease (myocardial infarction or sudden death before the
 age of 55 in the father/brother, myocardial infarction or sudden death before the age
 of 65 in the mother/sister)

 -  patient for whom a decision to start add-on treatment with Liraglutide has been made.

 Exclusion Criteria:

 - Protected adult Patient not affiliated to a national health insurance scheme Pregnant or
 breastfeeding woman Women who intend to become pregnant or of childbearing age and do not
 use adequate contraceptive methods.

 Antidiabetic treatment of the incretin family (GLP-1 agonist or DPP4 inhibitor) Severe
 renal failure (clearance <30ml/min according to Cockroft due to gadolinium injection)
 Claustrophobia / contraindication to MRI (compatible non-MRI implanted metallic material)
 History of hypersensitivity to gadoteric acid or gadolinium-based contrast agents and
 meglumine Hypersensitivity to VICTOZA® or any of the excipients History or presence of
 pancreatitis (acute or chronic) Chronic inflammatory bowel disease Diabetic gastroparesis
 Dysthyroidism